Reply to Alffenaar

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1766-

  Srivastava, Shashikant ^a   Pasipanodya, Jotam G ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

AREA UNDER THE CURVE; ASSAY; BLOOD SAMPLING; DRIED BLOOD SPOT TESTING; DRUG CONCENTRATION; DRUG EXPOSURE; DRUG MONITORING; DRUG TOXICITY; HUMAN; LETTER; OPTIMAL SAMPLING THEORY; PHARMACOKINETICS; PRIORITY JOURNAL; RELIABILITY; SAMPLING; THEORY; TUBERCULOSIS;

EID: 84861065570     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis271     Document Type: Letter

References (5)

1. Alffenaar JWC. Dried blood spot analysis combined with limited sampling models can advance TDM of TB drugs. J Infectious Dis 2012; 54:1765-6.
2. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
3. Dartois V. Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J Infect Dis 2011; 204:1827-9.
4. Edelbroek PM, Heijden JVD, Stolk LML. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009; 31:327-36.
5. Alffenaar JW, Kosterink JG, van Altena R, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010; 32:97-101.